Michael Weintraub, MD

@MWeintraubMD

Endocrinologist & Clin. Asst. Prof. @NYULangone | @WeillCornell and @Sloan_Kettering endocrine fellow alum. ABOM Diplomate. Opinions = own

New York, NY

Joined July 2008

826Following

4KFollowers

Michael Weintraub, MD@MWeintraubMD · Jul 23

📊 The Obesity Care Cascade 🏥 Where does the breakdown occur in those who have BMI >30 and those who seek a doctor for advice? 🤔 🔻 The largest drop-off (83.7% relative disengagement) occurred between trying to lose weight and seeking professional help 💔 🔻 The second…

MWeintraubMD's tweet image. 📊 The Obesity Care Cascade 🏥

Where does the breakdown occur in those who have BMI &gt;30 and those who seek a doctor for advice? 🤔

🔻 The largest drop-off (83.7% relative disengagement) occurred between trying to lose weight and seeking professional help 💔

🔻 The second…

3.0K

Michael Weintraub, MD@MWeintraubMD · Jul 17

“It’s frustrating to see the enormous political capital of the MAHA movement expended on actions like the proposed product formulation changes that have little chance of reducing prominent diet-related chronic diseases like obesity and type 2 diabetes,” Hall said in an email.…

SSTAT@statnews · Jul 17

Getting Coca-Cola to use cane sugar rather and ice cream manufacturers to stop their use of synthetic dyes are the latest achievements trumpeted by the Make America Healthy Again movement. trib.al/lks1Z4x

166

19.0K

Michael Weintraub, MD@MWeintraubMD · Jul 18

Francis Collins discussing the scientific brain drain due to the muzzling of scientists at the NIH. Sobering conversation, particularly given the Colbert Late Show has been canceled 😢 youtube.com/watch?v=lW9c6t…

845

Michael Weintraub, MD@MWeintraubMD · Jul 17

We've been slowly uptitrating Ozempic by using "clicks" for a while knowing it would improve tolerability. Great to see we now have data to back this method up!

DDaniel J Drucker@DanielJDrucker · Jul 17

Slower, flexible titration of semaglutide in 104 people with #T2D studied over 26 weeks improved adherence and reduced adverse events without compromising efficacy diabetesjournals.org/care/article/d…

17.0K

Michael Weintraub, MD@MWeintraubMD · Jul 16

Should hypercortisolism be added as a cause of type 2 diabetes? The ominous octet to become the noxious nine

PPuttingHealthFirst@NeilSkolnik · Jul 16

24% of people with difficult to control diabetes have HYPERCORTISOLISM..and treatment with Mifepristone helps decrease A1c by >1.4% . This is a Big Deal! Practice Changer....Listen to the details @UNC_SOM #MedEd #MedTwitter #MedicalEducation @TheAACE @MWeintraubMD @ADCESdiabetes

2.0K

Michael Weintraub, MD@MWeintraubMD · Jul 14

A fantastic talk by Dr. Jose Aleman on Weight Loss Pharmacotherapy in the Spectrum of Obesity Care at #ENDO2025

2.0K

Michael Weintraub, MD@MWeintraubMD · Jul 14

FRAX score is an online calculator to estimate someone’s risk of bone fracture. But it has limitations. FRAXplus has a many additional advantages by incorporating: ◦Recency of osteoporotic fracture ◦Higher than average exposure to oral glucocorticoids ◦Information on…

$MWeintraubMD's tweet image. FRAX score is an online calculator to estimate someone’s risk of bone fracture. But it has limitations. FRAXplus has a many additional advantages by incorporating: ◦Recency of osteoporotic fracture ◦Higher than average exposure to oral glucocorticoids ◦Information on…$

2.0K

Michael Weintraub, MD@MWeintraubMD · Jul 14

Primary aldosteronism is the most common cause of endocrine-related hypertension Dividing into unilateral and bilateral disease is a gross oversimplification Excellent talk by Dr. Michael Stowasser at #ENDO2025

MWeintraubMD's tweet image. Primary aldosteronism is the most common cause of endocrine-related hypertension

Dividing into unilateral and bilateral disease is a gross oversimplification

Excellent talk by Dr. Michael Stowasser at #ENDO2025

4.0K

Michael Weintraub, MD@MWeintraubMD · Jul 14

Rates of obesity are raising across the world. Except France! What are they doing right?

4.0K

Michael Weintraub, MD@MWeintraubMD · Jul 13

Rates of obesity of BMI 30-40 have had a mild increase over the last 20 years. Rates of severe obesity BMI > 60 has dramatically risen- this graph is impressive. Slide by Dr. Satya Dash at #ENDO2025

MWeintraubMD's tweet image. Rates of obesity of BMI 30-40 have had a mild increase over the last 20 years.

Rates of severe obesity BMI &gt; 60 has dramatically risen- this graph is impressive.

Slide by Dr. Satya Dash at #ENDO2025

2.0K

Michael Weintraub, MD@MWeintraubMD · Jul 13

Yet another study showing high discontinuation rate of both semaglutide and tirzepatide up to 50% at 1 year in the real world. Top discontinuation reasons included: • Side effects (36%) • Logistical challenges (24%) • Cost (23%) • Shortages (11%) • Inadequate weight loss…

MWeintraubMD's tweet image. Yet another study showing high discontinuation rate of both semaglutide and tirzepatide up to 50% at 1 year in the real world.

Top discontinuation reasons included:
• Side effects (36%)
• Logistical challenges (24%)
• Cost (23%)
• Shortages (11%)
• Inadequate weight loss…

128

20.0K

Michael Weintraub, MD@MWeintraubMD · Jul 13

Pheochromocytoma survival curves are dismal, particularly in those with metastatic disease. We need better treatments for these patients. Excellent lecture by Dr. Camilo Jimenez at #ENDO2025

MWeintraubMD's tweet image. Pheochromocytoma survival curves are dismal, particularly in those with metastatic disease. We need better treatments for these patients.

Excellent lecture by Dr. Camilo Jimenez at #ENDO2025

2.0K

Michael Weintraub, MD@MWeintraubMD · Jul 12

Excellent presentation by Dr. Angela Rao on peri-operative GLP1 use before and after bariatric surgery at #ENDO2025! @dimpi_desai

MWeintraubMD's tweet image. Excellent presentation by Dr. Angela Rao on peri-operative GLP1 use before and after bariatric surgery at #ENDO2025!
@dimpi_desai

2.0K

Michael Weintraub, MD@MWeintraubMD · Jul 12

The hunt for additional targets for obesity treatment is on. A novel coagonist of MC4R and GLP1 which as the potential to augment weight loss and glucose control. #ENDO2025

MWeintraubMD's tweet image. The hunt for additional targets for obesity treatment is on.

A novel coagonist of MC4R and GLP1 which as the potential to augment weight loss and glucose control.

#ENDO2025

2.0K